Trial Profile
Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well-Controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of cART
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MARCH
- 05 Apr 2016 Primary endpoint of comparison of the switch arms to control arm of proportions of participants with HIV RNA 200 copies/mL 48 weeks after randomisation has not been met, according to results published in the Clinical Infectious Disease.
- 05 Apr 2016 Results (n=395) published in the Clinical Infectious Diseases
- 19 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.